Phase 2 N=14 Lonafarnib for Chronic Hepatitis D
Hepatitis D
Primary: Change in Quantitative Serum HDV RNA Levels After 28 Days of Lonafarnib Therapy. — -0.13; -0.73; -1.54 log(IU/ml) — p=0.03
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=16 TAK-648 Multiple-Rising Dose Study in Healthy Japanese Participants and Non-Japanese Participants With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Percentage of Participants Who Have at Least 1 Treatment-Emergent Adverse Event (TEAE) for Part 1 — 83.3; 33.3; 100.0 percentage of participants
N/A N=13 Assessment of the Effect of Botulinum Toxin in Extensor Digitorum Brevis Via Strain Gauge and Nerve Conduction Studies
Muscle Strength · Botulinum Toxins, Type A
Primary: Change in Measured Force (Change From Baseline) (Using Strain Gauges) of Dorsiflexion of Digits 2 and 3 ("Force of EDB") After vs. Before Botulinum Toxin Injection Into…
N/A N=19 Does Increasing Auditory Cueing Affect Gait Parameters in Children With Cerebral Palsy During a Functional Task?
Cerebral Palsy · Children
Primary: Step Length as Measured by the Gaitrite Walk-way System. — 51.32; 53.36 cm
Phase 4 N=198 Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis
Schizophrenia
Primary: Percentage of Participants That Responded to Treatment — 62.8; 56.8 percentage of response — p=.61
N/A N=18 A Novel Positron Emission Tomography (PET) Approach to Measuring Myocardial Metabolism
Type 2 Diabetes Mellitus
Primary: Myocardial Fatty Acid Uptake Rate — 18.492; 2.123; 36.005; 7.8 umol/min/100g
Phase 3 N=89 Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody
Primary Hyperlipidemia and Mixed Dyslipidemia
Primary: Percent Change From Baseline in Low-density Lipoprotein (LDL) Apolipoprotein B-100 Fractional Catabolic Rate (FCR) — -5.07; 74.13; 83.70; 310.48 percent change — p=0.018
Phase 1 N=24 A Study to Assess the Relative Bioavailability and to Assess the Effect of Food on the Bioavailability of a TAK-648 Tablet in Healthy Participants
Healthy Volunteers
Primary: Cmax: Maximum Observed Plasma Concentration for TAK-648 — 4.504; 4.707; 5.185 mg/mL
N/A N=300 Investigational Multi-purpose Contact Lens Care Solution.
Contact Lens Wear
Primary: Slit Lamp Findings — 11; 16; 0; 0 Subjects Eyes
Phase 1 N=48 A Study to Assess the Relative Bioavailability of Process Variants of Selumetinib in Healthy Male Volunteers
Healthy Volunteers Bioequivalence or Bioavailability Study
Primary: Bioequivalence of the Free Base Variant of Selumetinib (Treatment B) Compared to the Blue Reference Capsule (Treatment A) [Selumetinib Cmax] — 1330; 124 nanograms per…
N/A N=9 Safety Study of Deep Brain Stimulation to Manage Thalamic Pain Syndrome
Chronic Pain
Primary: Number of Participants With 50% Improvement in Pain Related Disability (as Assessed by the Pain Disability Index) — 2; 0 participants
Phase 3 N=1,887 A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.
Urologic Diseases · Urinary Bladder, Overactive · Urinary Bladder Diseases
Primary: Change From Baseline to Final Visit in the Mean Number of Micturitions Per 24 Hours — -2.95; -3.13 micturitions — p=0.15
Phase 2 N=59 Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Carcinoma
Primary: Progression-free Survival (PFS) at 6-months — 28 percentage of participants
Phase 2 N=340 Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants
Hepatitis C · Chronic Pain
Primary: Percentage of Participants With Rapid Viral Response (RVR) After 4 Weeks of Treatment < the Limit of Quantification (RVR4LOQ) — 28.4; 36.9; 41.9; 84.6 percentage of…
Phase 2 N=517 Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Primary: Number of Participants With Treatment-emergent Adverse Events (AEs) — 61; 57; 70; 57 participants